Errin Manney, MD
Family Medicine · Frankfort, ILNPI 1912386236
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 240 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$696
- AbbVie$628
- Boehringer Ingelheim$444
- Lilly USA, LLC$422
- Pfizer$275
- Amgen$189
- plus $2K from 29 others
Across 30 payments — averaging $5411.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$83K
- Sumitomo Pharma America, Inc.$52K
- F. Hoffmann-la Roche AG$23K
- Genentech, Inc.$4K
What the payments were for
- Food & beverage$4,381100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $696 |
| AbbVie | 40 | $628 |
| Boehringer Ingelheim | 20 | $444 |
| Lilly USA, LLC | 27 | $422 |
| Pfizer | 16 | $275 |
| Amgen | 12 | $189 |
| Exact Sciences | 8 | $167 |
| GSK | 8 | $144 |
| AstraZeneca | 9 | $139 |
| Abbott | 6 | $125 |
| Johnson & Johnson | 6 | $118 |
| Bayer | 4 | $102 |
| Organon | 4 | $84 |
| Dexcom, Inc. | 2 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $70 |
| Merck | 3 | $60 |
| Ardelyx, Inc. | 2 | $60 |
| Phathom Pharmaceuticals, Inc. | 3 | $58 |
| Idorsia Pharmaceuticals US Inc | 4 | $58 |
| Corcept Therapeutics | 2 | $48 |
| Novartis | 2 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $45 |
| Philips North America LLC | 1 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Astellas Pharma US Inc | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Esperion Therapeutics, Inc. | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Exeltis, USA Inc. | 1 | $15 |
| Scynexis, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
How this compares
$4,381 in reported general payments places this provider in the 90th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $103,810 |
| JardianceEmpagliflozin | 54 | $75,751 |
| RybelsusSemaglutide | 28 | $59,104 |
| EliquisApixaban | 38 | $56,669 |
| JanuviaSitagliptin Phosphate | 18 | $28,389 |
| FarxigaDapagliflozin Propanediol | 22 | $27,239 |
| TrulicityDulaglutide | 17 | $21,723 |
| MounjaroTirzepatide | 11 | $15,211 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $11,941 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $10,374 |
| LinzessLinaclotide | 14 | $7,663 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 98 | $2,959 |
| Atorvastatin Calcium | 325 | $2,863 |
| Desloratadine | 51 | $2,230 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $2,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $696 | $162,91487 claims |
| Boehringer IngelheimJardiance | $444 | $75,75154 claims |
| PfizerEliquis | $275 | $56,66938 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $139 | $39,18039 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $422 | $36,93528 claims |
| MerckJanuvia | $60 | $28,38918 claims |
| AbbVieLinzess | $628 | $7,66314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Frankfort
- Frank PhillipsChicago$1.6M
- Peter TothSterling$1.4M
- Bradley TorphyChicago$1.3M
- Jeffrey RoyceRockford$890K
- Anthony AuriemmaWestmont$788K
- Manfred ManGurnee$764K
- Barbara BellarOakbrook Terrace$599K
- Bernie RancheroAltamont$533K
- Sandy GibsonChicago$309K
- Mandy GittlerChicago$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.